Meridian Medicaid does cover Zepbound, but only in narrow circumstances that depend on which state you live in and why the drug is being prescribed. In Michigan, Zepbound for weight loss is covered only if you meet four strict criteria that took effect January 1, 2026. In Illinois, Meridian excludes weight-loss coverage entirely, though Zepbound can still be authorized for obstructive sleep apnea under a separate policy.
Michigan Meridian Coverage for Weight Loss
Zepbound remains on the Michigan Meridian formulary as a Tier 2 (non-preferred) drug, which means prior authorization is required.1Meridian Health Plan of Michigan. Michigan Meridian Formulary 2026 To get that authorization when the drug is prescribed solely for weight loss, a patient must now meet all four of these conditions:
- A body mass index of 40 or higher (morbid obesity).
- Documented failure of other clinically appropriate weight-loss approaches.
- Trial and failure of preferred anti-obesity medications on Michigan’s Preferred Drug List, such as phentermine or Qsymia (phentermine plus topiramate).
- The prescription must be positioned specifically as a way to avoid bariatric surgery.
These rules come from Public Act 22 of 2025, Michigan’s fiscal year 2026 budget, which directed the state Medicaid program to sharply curtail GLP-1 coverage for obesity.2Michigan Legislature. House Bill 4706 The Michigan Department of Health and Human Services translated the law into pharmacy policy through L-Letter L 25-73.3Michigan Department of Health and Human Services. Update of Pharmacy Drug Coverage for Treatment of Obesity The same restrictions apply to Wegovy, Saxenda, and generic liraglutide.
The formulary sets a quantity limit of 2.4 mL per 28 days for the Zepbound KwikPen and 2 mL per 28 days for the SOAJ formulation, and the patient must be at least 18 years old.1Meridian Health Plan of Michigan. Michigan Meridian Formulary 2026
If you already had an active prior authorization when the new rules took effect, Meridian honored it for the remainder of that six-month approval. Renewal requests filed after expiration are evaluated under the new criteria, and notification letters went out in early December 2025.4Meridian Health Plan of Michigan. GLP-1 Benefit Reduction Bulletin
Michigan Coverage for Non-Weight-Loss Uses
The January 2026 restrictions apply only when Zepbound is prescribed for weight loss. Other medical uses run on different tracks.
Obstructive Sleep Apnea
The FDA approved Zepbound in late 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity.5PR Newswire. FDA Approves Zepbound for Moderate-to-Severe Obstructive Sleep Apnea in Adults With Obesity Michigan Medicaid continues to authorize Zepbound for OSA through a separate clinical category, still with prior authorization.6Michigan Medicaid. Michigan Medicaid Clinical and PDL Criteria
Type 2 Diabetes
Tirzepatide, the active ingredient in Zepbound, is also sold as Mounjaro for type 2 diabetes. Coverage for Mounjaro and other GLP-1s prescribed for diabetes was not affected by the 2026 changes.7Priority Health. Medicaid GLP-1 Coverage Changes Effective January 1, 2026 Federal Medicaid rules generally require states to cover FDA-approved drugs for medically accepted indications like diabetes, while giving states discretion to exclude anti-obesity drugs.8KFF. Medicaid Coverage of and Spending on GLP-1s
Cardiovascular Risk
Michigan Medicaid continues to cover Wegovy for patients who are overweight or obese and have established cardiovascular disease or severe liver disease.9University of Michigan Medical Research. Expert Q&A: Michigan Medicaid’s New Limits on GLP-1 Weight Management Medications Zepbound itself does not carry an FDA-approved cardiovascular indication.
Illinois Meridian: Weight Loss Is Excluded
Meridian’s Illinois Medicaid plan takes a harder line. Its clinical policy for GLP-1 receptor agonists states that “weight loss is a benefit exclusion and is not a covered benefit,” and GLP-1s are generally authorized only for type 2 diabetes.10Meridian Health Plan of Illinois. Glucagon-Like Peptide-1 Receptor Agonists Clinical Policy Zepbound is not on the Illinois Medicaid Preferred Drug List as of January 2026.11Illinois Department of Healthcare and Family Services. Illinois Medicaid Preferred Drug List
There is one exception. Meridian Illinois maintains a separate clinical policy for Zepbound prescribed for obstructive sleep apnea. To qualify, a patient must have:
- A BMI of 30 or higher.
- An OSA diagnosis confirmed by a sleep study.
- Documented participation in a physician-directed weight-loss program.
- Adherence to positive airway pressure (PAP) therapy, or documentation that PAP is not an option.
Even under the OSA pathway, the policy states that use of Zepbound for weight management “will not be authorized.”12Meridian Health Plan of Illinois. Tirzepatide (Zepbound) for OSA Clinical Policy
If Meridian Denies Your Prior Authorization
Given how tight these criteria are, denials are common. You have the right to appeal, and the process generally moves through the following steps:
- Read the denial letter closely. It should list the specific reason and the appeal deadline. Many plans allow 180 days; some require action within 60 to 65 days.
- Ask your prescriber for a Letter of Medical Necessity that speaks directly to the reason for the denial. It should include current BMI, weight history, comorbidities with ICD-10 codes, previous weight-loss attempts, and the clinical rationale for Zepbound.
- Submit an internal appeal. Insurers generally must respond within 30 days for a standard appeal or 72 hours for an urgent one.
- Request an independent external review if the internal appeal fails. According to available guidance, external reviews overturn roughly 40% of denials that reach that stage.
If your BMI is below the morbid-obesity threshold but you have moderate-to-severe obstructive sleep apnea, filing under the OSA indication rather than weight management can be the difference between approval and denial.12Meridian Health Plan of Illinois. Tirzepatide (Zepbound) for OSA Clinical Policy
What Could Change: The Federal BALANCE Model
A federal initiative may eventually widen access. The CMS BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive Health) lets state Medicaid agencies opt into a framework where CMS negotiates GLP-1 pricing directly with manufacturers. States can begin joining as of May 2026, and the application deadline is July 31, 2026.13KFF. What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid
The model explicitly includes the Zepbound KwikPen, along with Wegovy, Ozempic, Mounjaro, Rybelsus, and orforglipron if approved. Participating states must follow the model’s standardized coverage criteria and cannot make them more restrictive, though they can offer broader coverage. Prior authorization still applies.14Centers for Medicare & Medicaid Services. BALANCE Model Whether Michigan or Illinois will join has not been announced, but for Meridian enrollees in either state, BALANCE is currently the clearest path to broader Zepbound access.